❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Cancer Genetics ❭ Translational studies on solid tumours [Helland] ❭ Clinical trials ❭ MATRIX-RARE ❭

MATRIX-RARE

– Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment; matrixrare.no

  • EudraCT number: 2024-513779-42-02
  • Clinicaltrials.gov: NCT06119789
Background/study objectives
Study design
Collaborative partners
Update/publications
Scroll to top

Home Dept. of Cancer Genetics Translational studies on solid tumours [Helland]

  • Group members
  • Clinical trials
    • DART
    • NIPU
    • COM-IT-2
    • MATRIX-RARE
    • IMPRESS-Norway
  • Translational studies
  • Publications
  • News

Recent publications

Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS (2025)
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
Cell Death Dis, 16 (1), 555
DOI 10.1038/s41419-025-07884-7, PubMed 40701968

Stålberg SM, Silwal-Pandit L, Hamfjord J, Nebdal DJH, Lehtiö J, Lingjærde OC, Skålhegg BS, Kure EH (2025)
Elevated KRAS protein level is associated with better survival in pancreatic cancer
BMC Cancer, 25 (1), 1080
DOI 10.1186/s12885-025-14461-w, PubMed 40596921

Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C (2025)
Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
Pharmacoepidemiol Drug Saf, 34 (7), e70181
DOI 10.1002/pds.70181, PubMed 40552731

More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)